Limit this search to....

Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report
Contributor(s): National Academies of Sciences Engineeri (Author), Health and Medicine Division (Author), Board on Population Health and Public He (Author)
ISBN: 0309437997     ISBN-13: 9780309437998
Publisher: National Academies Press
OUR PRICE:   $60.80  
Product Type: Paperback
Published: July 2016
Qty:
Temporarily out of stock - Will ship within 2 to 5 weeks
Additional Information
BISAC Categories:
- Medical | Infectious Diseases
- Medical | Public Health
Dewey: 614.593
LCCN: 2017303136
Physical Information: 0.6" H x 6" W x 8.9" (0.75 lbs) 186 pages
 
Descriptions, Reviews, Etc.
Publisher Description:

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide.

The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.